S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
Biden’s Big Lie… (Ad)pixel
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
5 Hypergrowth Stocks to Buy Now (Ad)pixel
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
5 Hypergrowth Stocks to Buy Now (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
Biden’s Big Lie… (Ad)pixel
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
5 Hypergrowth Stocks to Buy Now (Ad)pixel
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
5 Hypergrowth Stocks to Buy Now (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
Biden’s Big Lie… (Ad)pixel
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
5 Hypergrowth Stocks to Buy Now (Ad)pixel
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
5 Hypergrowth Stocks to Buy Now (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
Biden’s Big Lie… (Ad)pixel
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
5 Hypergrowth Stocks to Buy Now (Ad)pixel
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
5 Hypergrowth Stocks to Buy Now (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
NASDAQ:FOLD

Amicus Therapeutics - FOLD Stock Forecast, Price & News

$11.09
+0.18 (+1.65%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$11.00
$11.21
50-Day Range
$10.91
$13.54
52-Week Range
$5.91
$13.84
Volume
2.20 million shs
Average Volume
2.23 million shs
Market Capitalization
$3.14 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.20

Amicus Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
37.1% Upside
$15.20 Price Target
Short Interest
Bearish
7.39% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.25
Upright™ Environmental Score
News Sentiment
0.76mentions of Amicus Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$4.63 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.38) to $0.20 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

624th out of 1,004 stocks

Pharmaceutical Preparations Industry

306th out of 489 stocks


FOLD stock logo

About Amicus Therapeutics (NASDAQ:FOLD) Stock

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.

Receive FOLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FOLD Stock News Headlines

Banking Nightmare
During and after the Great Financial Crisis of 2008, 485 U.S. banks went under. Here at Weiss Ratings, we warned about 484 — an accuracy rate of 99.8%. Now, we have a new warning. But this time, it's not just about a few hundred banks … it's about nearly every single bank in America …
Biden's corruption knows no end
Porter Stansberry here -- I reveal the shocking changes this Obama policy will usher in… what it means for you, your family, and your finances… and how you can prepare for this new American era. Stream my new documentary at no cost today.pixel
Q4 2022 Amicus Therapeutics Inc Earnings Call
Earnings Preview: Amicus Therapeutics
BTIG Reaffirms Their Buy Rating on Amicus (FOLD)
See More Headlines
Receive FOLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FOLD Company Calendar

Last Earnings
11/08/2021
Today
4/01/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:FOLD
CUSIP
03152W10
Employees
496
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$15.20
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+37.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
5 Analysts

Profitability

Net Income
$-236,570,000.00
Pretax Margin
-73.52%

Debt

Sales & Book Value

Annual Sales
$329.23 million
Book Value
$0.44 per share

Miscellaneous

Free Float
275,930,000
Market Cap
$3.14 billion
Optionable
Optionable
Beta
0.82

Social Links


Key Executives

  • Bradley Lewis CampbellBradley Lewis Campbell
    President, Chief Executive Officer & Director
  • Daphne E. Quimi
    Chief Financial Officer
  • Jill Weimer
    Chief Science Officer
  • Mitchell Goldman
    Chief Medical Officer
  • Patrik S. Florencio
    Senior VP, Global Chief Compliance & Risk Officer













FOLD Stock - Frequently Asked Questions

Should I buy or sell Amicus Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FOLD shares.
View FOLD analyst ratings
or view top-rated stocks.

What is Amicus Therapeutics' stock price forecast for 2023?

5 Wall Street research analysts have issued 12-month price targets for Amicus Therapeutics' stock. Their FOLD share price forecasts range from $11.00 to $17.00. On average, they predict the company's share price to reach $15.20 in the next year. This suggests a possible upside of 37.1% from the stock's current price.
View analysts price targets for FOLD
or view top-rated stocks among Wall Street analysts.

How have FOLD shares performed in 2023?

Amicus Therapeutics' stock was trading at $12.21 at the beginning of the year. Since then, FOLD shares have decreased by 9.2% and is now trading at $11.09.
View the best growth stocks for 2023 here
.

Are investors shorting Amicus Therapeutics?

Amicus Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 20,880,000 shares, an increase of 15.4% from the February 28th total of 18,090,000 shares. Based on an average trading volume of 2,120,000 shares, the days-to-cover ratio is currently 9.8 days.
View Amicus Therapeutics' Short Interest
.

When is Amicus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our FOLD earnings forecast
.

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) announced its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.01. The biopharmaceutical company had revenue of $79.55 million for the quarter, compared to analysts' expectations of $81.42 million. Amicus Therapeutics had a negative trailing twelve-month return on equity of 141.73% and a negative net margin of 71.83%. During the same quarter in the prior year, the firm posted ($0.22) EPS.

What guidance has Amicus Therapeutics issued on next quarter's earnings?

Amicus Therapeutics updated its FY 2022 earnings guidance on Monday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $329.00 million-$329.00 million, compared to the consensus revenue estimate of $326.68 million.

What is John F. Crowley's approval rating as Amicus Therapeutics' CEO?

21 employees have rated Amicus Therapeutics Chief Executive Officer John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among the company's employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amicus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

How do I buy shares of Amicus Therapeutics?

Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amicus Therapeutics' stock price today?

One share of FOLD stock can currently be purchased for approximately $11.09.

How much money does Amicus Therapeutics make?

Amicus Therapeutics (NASDAQ:FOLD) has a market capitalization of $3.14 billion and generates $329.23 million in revenue each year. The biopharmaceutical company earns $-236,570,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.

How many employees does Amicus Therapeutics have?

The company employs 496 workers across the globe.

How can I contact Amicus Therapeutics?

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The official website for the company is www.amicusrx.com. The biopharmaceutical company can be reached via phone at (215) 921-7600, via email at afaughnan@amicusrx.com, or via fax at 609-662-2001.

This page (NASDAQ:FOLD) was last updated on 4/1/2023 by MarketBeat.com Staff